NCT00324428

Brief Summary

This is a phase II study that aims to investigate prospectively a new therapy for a cohort of patients with chronic pain attributed to pancreatic cancer. The justification of this study is that the pain is the most important factor for the quality of life of these patients and rTMS has been shown to be significantly associated with pain improvement in patients with abdominal pain due to chronic pancreatitis. This therapeutic trial will be a 10-day, randomized, parallel-group design, double-blind, incomplete cross-over, placebo controlled clinical trial conducted at Beth Israel Deaconess Medical Center. The principal aim of this investigation is the study of pain after a therapeutic intervention. The primary outcome is pain reduction indexed by pain reduction and or analgesic intake reduction. The second aim of the study is to assess the safety this new treatment in patients with pancreatic cancer. The third aim of this study is to investigate whether rTMS treatment is associated with a change in the activity of right secondary somatosensory cortex using magnetic resonance spectroscopy. Because patients with locally advanced or advanced pancreatic cancer often require increasing doses of narcotic pain medications, such as morphine, oxycodone and fentanyl, in order to control their pain, adverse side effects are frequent observed in this population of patients. Therefore rTMS treatment might represent a new therapeutic approach that might be useful not only for pancreatic cancer but also to other types of cancer.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
3

participants targeted

Target at below P25 for not_applicable pain

Timeline
Completed

Started May 2006

Longer than P75 for not_applicable pain

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 1, 2006

Completed
9 days until next milestone

First Submitted

Initial submission to the registry

May 10, 2006

Completed
1 day until next milestone

First Posted

Study publicly available on registry

May 11, 2006

Completed
5.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2011

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2011

Completed
Last Updated

March 21, 2017

Status Verified

March 1, 2017

Enrollment Period

5.5 years

First QC Date

May 10, 2006

Last Update Submit

March 17, 2017

Conditions

Keywords

TMSVisceral PainAnalgesiaPancreatic CancerCancerElectric stimulation therapyElectric stimulationPainSafety

Outcome Measures

Primary Outcomes (1)

  • Pain (visual analog scale, CGI,PGA); Medication use (medication diary)

    1 year

Secondary Outcomes (1)

  • Safety (cognitive assessment - neuropsychological battery)

    1 year

Study Arms (2)

Transcranial Magnetic Stimulation (TMS)

EXPERIMENTAL

This arm provides active 1Hz repetitive TMS (rTMS) applied to SII

Procedure: Transcranial Magnetic Stimulation

Transcranial Magnetic Stimulation Sham

SHAM COMPARATOR

This arm provides sham 1Hz repetitive TMS (rTMS) applied to SII

Procedure: Transcranial Magnetic Stimulation

Interventions

1Hz repetitive transcranial magnetic stimulation for 10 days 26 minutes each day

Transcranial Magnetic Stimulation (TMS)Transcranial Magnetic Stimulation Sham

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Locally advanced or metastatic pancreatic cancer
  • Abdominal pain attributable to pancreatic cancer that requires daily narcotic use
  • Stable narcotic dosage the week before study entry
  • A computed tomography of the abdomen within four weeks of study entry
  • CA19-9 within four weeks of study entry
  • ECOG Performance status \>=3

You may not qualify if:

  • Known brain metastasis
  • Patients with major depression with suicidal risk
  • Prior neurosurgical procedures
  • History of epilepsy
  • Previous head injury
  • History of Stroke
  • Abnormal neurological examination other than as signs of the condition studied in the present protocol
  • Contraindication to TMS:
  • Implanted pacemaker;Medication pump;Vagal stimulator;Deep brain stimulator;Metallic hardware in the head or scalp: shrapnel, surgical clips, or fragments from welding;Signs of increased intracranial pressure
  • TENS unit and ventriculo-peritoneal shunt
  • Pregnancy
  • Unable to undergo a brain MR
  • claustrophobia refractory to anxiolytics
  • ferromagnetic metal in the body such as a prosthetic heart valve, a pacemaker, or a brain aneurysm clip).

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Beth Israel Deaconess Medical Center

Boston, Massachusetts, 02215, United States

Location

Related Links

MeSH Terms

Conditions

PainVisceral PainPancreatic NeoplasmsAgnosiaNeoplasms

Interventions

Transcranial Magnetic Stimulation

Condition Hierarchy (Ancestors)

Neurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and SymptomsNociceptive PainDigestive System NeoplasmsNeoplasms by SiteEndocrine Gland NeoplasmsDigestive System DiseasesPancreatic DiseasesEndocrine System DiseasesPerceptual DisordersNeurobehavioral ManifestationsNervous System Diseases

Intervention Hierarchy (Ancestors)

Magnetic Field TherapyTherapeutics

Study Officials

  • Felipe Fregni, MD, PhD

    Beth Israel Deaconess Medical Center

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

May 10, 2006

First Posted

May 11, 2006

Study Start

May 1, 2006

Primary Completion

November 1, 2011

Study Completion

November 1, 2011

Last Updated

March 21, 2017

Record last verified: 2017-03

Locations